SK3 Group's Berkeley Bio Organic Research Laboratories Has Developed Cutting Edge Nutritional Supplement, Alzatrex(TM), Targe...
March 11 2014 - 09:15AM
Marketwired
SK3 Group's Berkeley Bio Organic Research Laboratories Has
Developed Cutting Edge Nutritional Supplement, Alzatrex(TM),
Targeted to Assist Those With Memory Deficits and to Reduce Brain
Fog From MMJ Use
LOS ANGELES, CA--(Marketwired - Mar 11, 2014) - SK3
Group's (OTC Pink: SKTO) (PINKSHEETS: SKTO) Berkeley Bio
Organic Research Laboratories has developed "Alzatrex"™, an herbal
supplement that may be taken orally that combines medical cannabis
with a proprietary formula of herbal COX-2
inhibitors. Research has shown that Δ9-THC, the main active
ingredient in medical marijuana, decreases β-amyloid plaques and
neurodegeneration in Alzheimer's disease, and that it is reduced
further by the addition of a COX-2 inhibitor. A COX-2
inhibitor is a form of NSAID that is used to reduce pain.
The combination of a COX-2 inhibitor with medical cannabis also
prevents marijuana-induced memory problems and "brain fog" or
"haze" that is common. Further, as stated in the journal Cell,
"These results suggest that the applicability of medical marijuana
would be broadened by concurrent inhibition of
COX-2." See Cell, Chen et al.: "Δ9-THC-caused
synaptic and memory impairments are mediated through COX-2
signaling", at
http://www.cell.com/retrieve/pii/S0092867413013603?cc=y.
Although the Centers for Disease Control and Prevention has
estimated that 5 million Americans are living with Alzheimer's
disease, and that 83,000 die from the condition every year, a new
study has found that nearly half a million elderly Americans likely
died from Alzheimer's disease in 2010, which is almost 6 times
higher than previous estimates according to a new study released
Wednesday. This moves Alzheimer's from the sixth-leading cause
of death in the U.S. to the third-leading killer, right behind
heart disease and cancer. See Neurology,
"Contribution of Alzheimer disease to mortality in the United
States" at
http://www.neurology.org/content/early/2014/03/05/WNL.0000000000000240.short?sid=fba9c422-3628-4a5c-ad91-7f4bd0bc4e28.
Furthermore, COX inhibitors have been shown to reduce the
occurrence of cancers and pre-cancerous growths.
Artemus Mayor, President of SK3 Group, Inc., said, "We see this
as an opportunity to help the many people suffering with
Alzheimer's disease. Our new Alzatrex™ product will not only
help those with Alzheimer's and dementia, but it will also help
medical marijuana patients reduce the side-effects of cannabis,
mainly the 'brain fog' that is so common. We are using technology
to improve the lives of patients."
Alzatrex™ will be available soon in dispensaries and delivery
services across California, to start.
About SKTO SK3 is a healthcare logistics and fulfillment
consultancy focused on the delivery of alternative care and
medicine. With seasoned management, breakthrough technology and
best practices, SK3 brings standardization and transparency to this
rapidly growing segment of the alternative care field.
FDA Statement The statements in this document have not
been evaluated or approved by the FDA. The products and statements
referenced in this document are not intended to diagnose, treat,
cure, or prevent any disease.
Safe Harbor Statement This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based on the
current plans and expectations of management and are subject to a
number of uncertainties and risks that could significantly affect
the company's current plans and expectations, as well as future
results of operations and financial condition. A more extensive
listing of risks and factors that may affect the company's business
prospects and cause actual results to differ materially from those
described in the forward-looking statements can be found in the
reports and other documents filed by the company with the
Securities and Exchange Commission. The company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
SK3 Group Investor Relations investors@medicalgreens.com
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Feb 2024 to Mar 2024
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Mar 2023 to Mar 2024